Recombinant analogue of the human protein SLURP-1 inhibits the growth of multicellular carcinoma cell spheroids

Cover Page

Cite item

Full Text

Abstract

The present study showed that the recombinant analogue of SLURP‑1 effectively inhibits the growth of a 3D model of tumors - multicellular spheroids from human epidermoid carcinoma A431 cells and human lung adenocarcinoma A549 cells. The combined application of SLURP‑1 with gefitinib (inhibitor of epidermal growth factor receptor (EGFR)) leads to the synergistic antiproliferative effect on spheroids from A431 cells. The results obtained suggest the possibility for design of first-in-class anticancer drugs based on recombinant SLURP‑1.

About the authors

M. L. Bychkov

Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Email: mikhailshulepko@gmail.com
Russian Federation, 16/10, Miklukho-Maklaya Street, Moscow, 117997

M. A. Shulepko

Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Author for correspondence.
Email: mikhailshulepko@gmail.com
Russian Federation, 16/10, Miklukho-Maklaya Street, Moscow, 117997

O. V. Shlepova

Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Moscow Institute of Physics and Technology

Email: mikhailshulepko@gmail.com
Russian Federation, 16/10, Miklukho-Maklaya Street, Moscow, 117997; 9, Institutskij, Dolgoprudny, Moscow region, 141701

E. N. Lyukmanova

Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Moscow Institute of Physics and Technology

Email: ekaterina-lyukmanova@yandex.ru
Russian Federation, 16/10, Miklukho-Maklaya Street, Moscow, 117997; 9, Institutskij, Dolgoprudny, Moscow region, 141701

M. P. Kirpichnikov

Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Lomonosov Moscow State University

Email: mikhailshulepko@gmail.com

Academician of the Russian Academy of Sciences

Russian Federation, 16/10, Miklukho-Maklaya Street, Moscow, 117997; 1, Leninskie gory, Moscow, 119991

References

  1. Grando S.A. // Nat. Rev. Cancer. 2014. V. 14. P. 419-429. doi: 10.1038/nrc3725.
  2. Schaal C., Chellappan S.P. // Mol. Cancer Res. MCR. 2014. V. 12. P. 14-23. doi: 10.1158/1541-7786.MCR 13-0541.
  3. Шулепко М.А., Кульбацкий Д.С., Бычков М.Л. и др. // Биоорг. химия. 2019. Т. 45 (3). С. 227-237. doi: 10.1134/S1068162019020122.
  4. Russo P., Cardinale A., Margaritora S., et al. // Life Sci. 2012. V. 91. P. 1087-1092. doi: 10.1016/j.lfs.2012. 05.003.
  5. Grozio A., Paleari L., Catassi A., et al. // Int. J. Cancer. 2008. V. 122. P. 1911-1915. doi: 10.1002/ijc.23298.
  6. Васильева Н.А., Локтюшов Е.В., Бычков М.Л. и др. // Усп. биол. химии. 2017. Т. 57. С. 303-330. doi: 10.1134/S0006297917130090.
  7. Bergqvist C., Kadara H., Hamie L., et al. // Int. J. Dermatol. 2018. V. 57. P. 162-170. doi: 10.1111/ijd.13850.
  8. Pettersson A., Nylund G., Khorram-Manesh A., et al. // Auton. Neurosci. Basic Clin. 2009. V. 148. P. 97-100. doi: 10.1016/j.autneu.2009.03.002.
  9. Russo P., Cardinale A., Margaritora S., et al. // Life Sci. 2012. V. 91. P. 1087-1092. doi: 10.1016/j.lfs.2012. 05.003.
  10. Arredondo J., Chernyavsky A.I., Grando S.A. // Life Sci. 2007. V. 80. P. 2243-2247. doi: 10.1016/j.lfs.2007. 01.003.
  11. Kalantari-Dehaghi M., Bernard H.-U., Grando S.A. // Life Sci. 2012. V. 91. P. 1122-1125. DOI: 10.1016/ j.lfs.2012.02.004.
  12. Throm V.M., Männle D., Giese T., et al. // Oncotarget. 2018. V. 9. P. 11734-11751. doi: 10.18632/oncotarget.24312.
  13. Lyukmanova E.N., Shulepko M.A., Kudryavtsev D., et al. // PloS One. 2016. V. 11. P. e0149733. doi: 10.1371/journal.pone.0149733.
  14. Lyukmanova E., Bychkov M., Sharonov G., et al. // Br. J. Pharmacol. 2018. V. 175. P. 1973-1986. doi: 10.1111/bph.14194.
  15. Riedl A., Schlederer M., Pudelko K., et al. // J. Cell Sci. 2017. V. 130. P. 203-218. doi: 10.1242/jcs. 188102.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Russian academy of sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies